New Parkinson's drug candidate passes first safety check in healthy volunteers
Knowledge-focused
Completed
This early-stage study tested a new oral drug, ATH-399A, in 76 healthy adults to see if it is safe and how the body processes it. The goal is to gather information needed to develop a treatment for Parkinson's disease. Participants took single or multiple doses, and researchers a…
Phase: PHASE1 • Sponsor: HanAll BioPharma Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:52 UTC